Literature DB >> 25926039

High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?

B A Mahal1, M-H Chen2, C L Bennett3, M W Kattan4, O Sartor5, K Stein6, A V D'Amico7, P L Nguyen8.   

Abstract

BACKGROUND: Although commonly used, early initiation of salvage androgen deprivation therapy (ADT) has not been proven to enhance survival. We evaluated whether prostate-specific antigen (PSA) anxiety or health literacy are associated with use of early salvage ADT among men with recurrent prostate cancer after radiotherapy. PATIENTS AND METHODS: The prospective Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma Registry was used to study 375 men with biochemically recurrent prostate cancer after external beam radiation or brachytherapy. Multivariable logistic regression was used to determine whether PSA anxiety and health literacy are associated with salvage ADT as initial management after biochemical recurrence.
RESULTS: Sixty-eight men (18.1%) received salvage ADT as initial management for PSA recurrence. Men with high PSA anxiety were twice as likely to receive salvage ADT compared with men who did not have high PSA anxiety on both univariable [28.8% versus 13.1%; odds ratio (OR) 2.15; 95% confidence interval (CI) 1.16-4.00; P = 0.015] and multivariable analysis [adjusted OR (AOR) 2.36; 95% CI 1.21-4.62; P = 0.012]. Furthermore, men who had higher levels of health literacy were nearly half as likely to undergo salvage ADT compared with men who had lower levels of health literacy on univariable analysis (15.2% versus 26.3%; OR 0.50; 95% CI 0.29-0.88; P = 0.016), with a trend toward this association on multivariable analysis (AOR 0.58; 95% CI 0.32-1.05; P = 0.07).
CONCLUSIONS: Among men with PSA recurrence after radiotherapy, odds of use of salvage ADT were nearly twice as great among men with high PSA anxiety or low health literacy, suggesting that these men are receiving higher rates of unproven treatment. Given that early salvage ADT is costly, worsens quality of life, and has not been shown to improve survival, quality improvement strategies are needed for these individuals.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  androgen deprivation therapy; health policy; prostatic neoplasm; recurrence; salvage therapy

Mesh:

Substances:

Year:  2015        PMID: 25926039      PMCID: PMC4478973          DOI: 10.1093/annonc/mdv185

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  30 in total

1.  Heeding our words: complexities of research among low-literacy populations.

Authors:  Melissa A Simon; Xinqi Dong; Narissa Nonzee; Charles L Bennett
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

Review 2.  Patient preferences in prostate cancer: a clinician's guide to understanding health utilities.

Authors:  Karen M Kramer; Charles L Bennett; A Simon Pickard; E Allison Lyons; Michael S Wolf; June M McKoy; Sara J Knight
Journal:  Clin Prostate Cancer       Date:  2005-06

3.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

Review 4.  The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.

Authors:  D P Lubeck; G D Grossfeld; P R Carroll
Journal:  Urology       Date:  2001-08       Impact factor: 2.649

Review 5.  Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.

Authors:  Celestia S Higano
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

6.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

7.  Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.

Authors:  M D Krahn; K E Bremner; J Luo; S M H Alibhai
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

8.  Development and validation of a short-form, rapid estimate of adult literacy in medicine.

Authors:  Ahsan M Arozullah; Paul R Yarnold; Charles L Bennett; Robert C Soltysik; Michael S Wolf; Rosario M Ferreira; Shoou-Yih D Lee; Stacey Costello; Adil Shakir; Caroline Denwood; Fred B Bryant; Terry Davis
Journal:  Med Care       Date:  2007-11       Impact factor: 2.983

9.  The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.

Authors:  David M Latini; Stacey L Hart; Sara J Knight; Janet E Cowan; Phillip L Ross; Janeen Duchane; Peter R Carroll
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450

10.  Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study.

Authors:  William Dale; Joshua Hemmerich; Kathryn Bylow; Supriya Mohile; Mary Mullaney; Walter M Stadler
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

View more
  6 in total

1.  Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study.

Authors:  F Casas; I Henríquez; A Bejar; X Maldonado; A Alvarez; C González-Sansegundo; A Boladeras; F Ferrer; A Hervás; I Herruzo; M Caro; I Rodriguez; C Ferrer
Journal:  Clin Transl Oncol       Date:  2016-10-21       Impact factor: 3.405

2.  Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality.

Authors:  Brandon A Mahal; Ming-Hui Chen; Andrew A Renshaw; Marian J Loffredo; Philip W Kantoff; Anthony V D'Amico
Journal:  J Natl Compr Canc Netw       Date:  2018-06       Impact factor: 11.908

Review 3.  Male sexual dysfunction and rehabilitation strategies in the settings of salvage prostate cancer treatment.

Authors:  Eric Chung
Journal:  Int J Impot Res       Date:  2021-04-14       Impact factor: 2.896

4.  The role of health literacy in cancer care: A mixed studies systematic review.

Authors:  Chloe E Holden; Sally Wheelwright; Amélie Harle; Richard Wagland
Journal:  PLoS One       Date:  2021-11-12       Impact factor: 3.240

Review 5.  Fear of cancer recurrence and PSA anxiety in patients with prostate cancer: a systematic review.

Authors:  Callum James; Oliver Brunckhorst; Omar Eymech; Robert Stewart; Prokar Dasgupta; Kamran Ahmed
Journal:  Support Care Cancer       Date:  2022-02-01       Impact factor: 3.359

Review 6.  Depression and prostate cancer: implications for urologists and oncologists.

Authors:  Christopher F Sharpley; David R H Christie; Vicki Bitsika
Journal:  Nat Rev Urol       Date:  2020-07-30       Impact factor: 14.432

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.